The choices you make today can impact Anna’s future1,2
Anna today: 50 years old
- Full-time teacher and mother of 2 teenagers
- Living with T2D and CKD for 6 years
Kidney profile
- Albuminuria: 50 mg/g
(+12 mg/g in the past year) - eGFR: 59 mL/min/1.73 m2
(-5 mL/min/1.73 m2 in the past year)
CV profile
- Family history of CV disease
Current medications:
- Statins
- Maximum tolerated dose of an ACEi
- T2D medications* (HbA1c: 7.7%)
Anna in the future
- Working only part time
- Less active family life due to health concerns
- Increased doses for both dyslipidemia and T2D medications
Kidney profile
- Albuminuria: 310 mg/g
- eGFR: 42 mL/min/1.73 m2
CV profile
- Coronary artery disease
- Symptomatic HFpEF
Patients with CKD are at increased risk for CV events2
Without additional intervention, Anna’s risk will grow
Increased albuminuria is associated with greater CV and renal risk3,4
Risk of CV mortality or end-stage renal
disease in patients with T2D†
Adapted from Fox et al. 2012
Take action now to help prevent further CV and renal damage2
The choices you make today can impact Brian’s future1,2
Brian today: 50 years old
- Newly retired, but busy grandfather of 2
- Living with T2D and CKD for 10 years
- Had an NSTEMI 3 years ago
Kidney profile
- Albuminuria: 50 mg/g
(+12 mg/g in the past year) - eGFR: 59 mL/min/1.73 m2
(-5 mL/min/1.73 m2 in the past year)
Current medications:
- Statins
- Aspirin
- Beta blocker
- T2D medications* (HbA1c: 7.7%)
- Calcium channel blocker
- Diuretic
- Maximum tolerated dose of an ACEi
Brian in the future
- Retired; less active family life due to health concerns
- Increased doses for both dyslipidemia and T2D medications
Kidney profile
- Albuminuria: 360 mg/g
- eGFR: 38 mL/min/1.73 m2
CV profile
- Has symptomatic HFpEF
Patients with CKD are at increased risk for CV events2
Without additional intervention, Brian’s risk will grow
Increased albuminuria is associated with greater CV and renal risk3,4
Risk of CV mortality or end-stage renal
disease in patients with T2D†
Adapted from Fox et al. 2012
Take action now to help prevent further CV and renal damage
The choices you make today can impact Maggie’s future1,2
Maggie today: 60 years old
- Works full time as a teacher and is a grandmother with an active family life
- Living with T2D and CKD for 8 years
Kidney profile
- Albuminuria: 280 mg/g
(+65 mg/g in the past year) - eGFR: 54 mL/min/1.73 m2
(-10 mL/min/1.73 m2 in the past year)
Current medications:
- Statins
- Multiple T2D medications* (HbA1c: 7.7%)
- Calcium channel blocker
- Diuretic
- Maximum tolerated dose of an ACEi
Maggie in the future
- Working only part time
- Less active family life due to health concerns
Kidney profile
- Albuminuria: 780 mg/g
- eGFR: 40 mL/min/1.73 m2
CV risk factors
- Diagnosed with HFpEF
Medication changes:
- Increased doses for both dyslipidemia
and T2D medications
Patients with CKD are at increased risk for both renal and CV events2
Without additional intervention, Maggie’s risk will grow
Increased albuminuria is associated with greater CV and renal risk3,4
Risk of CV mortality or end-stage renal
disease in patients with T2D†
Adapted from Fox et al. 2012
Take action now to help prevent further CV and renal damage
| * | T2D medications may include insulin, biguanides (metformin), GLP-1 receptor agonists, and SGLT2 inhibitors.1 |
| † | Based on a meta-analysis of 1,024,977 patients from general population, high-risk CV, and CKD cohorts selected according to Chronic Kidney Prognosis Consortium criteria.4 |
ACEi=angiotensin-converting enzyme inhibitor; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; GLP-1=glucagon-like peptide-1; HbA1c=glycated haemoglobin; HFpEF=heart failure with preserved ejection fraction; SGLT2=sodium-glucose cotransporter 2; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.
References:
- Firialta® Product Insert approved by NPRA 4th April 2024. Return to content
- Agarwal R, et al. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777. Return to content
- Inoue K, et al. Ann Epidemiol. 2021;55:15-23. doi:10.1016/j.annepidem.2020.12.004. Return to content
- Fox CS, et al. Lancet. 2012;380:166-173. doi:10.1016/S0140-6736(12)61350-6. Return to content
© 2024 Bayer MY
This website was created by Bayer
and is intended to provide information to
healthcare professionals in Malaysia only.
PP-Fi-MY-0037-1 (10/24)
